Passar para o conteúdo principal

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexão rápida

Gastrointestinal API Products

Gastrointestinal API Products Manufacturer and Supplier

Dr. Reddy's offers a wide selection of Gastrointestinal APIs in the class of molecules that include - Proton pump inhibitors, H2-receptor antagonists, 5-HT3 receptor antagonists, laxatives, etc. We have established leaders in the GI therapeutic area, i.e., Proton pump inhibitors and the market leaders in the Prazole franchise APIs. As a Gastrointestinal API manufacturer and Gastrointestinal API supplier, Dr. Reddy's manufactures large volumes of gastrointestinal APIs consistently to cater to global demand and can offer a customized particle size distribution to meet our customer formulation needs.

Dr. Reddy’s Gastrointestinal APIs for various therapeutic categories are as follows:

Proton Pump Inhibitors

Proton Pump Inhibitors - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies


Anti-emetic - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

H2-receptor antagonists

H2-receptor antagonists - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

PBC, Non-alcoholic steatohepatitis

PBC, Non-alcoholic steatohepatitis - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

USPs of Gastrointestinal API

  • Customized Particle Size Distribution
  • Multiple manufacturing units
  • High degree of supply assurance
  • Vertically Integrated
  • Manufacture capacity of 100 multi-tones of prazole APIs
  • Supplier to 50 pharma companies across more than 25 countries for Gastrointestinal APIs.
  • Well-positioned to meet the global demand for high quality Prazole APIs
  • Active DMFs in all key markets
  • Proven track record as strong player in Prazole family both as APIs and Finished formulations
  • Multiple PSD Specs in place with validated size reduction process
  • Nitrosamine impurities assessment reports available
  • Meets Pharmacopeia requirements for US, EU, China, and Japan
  • Manufacturing and supply chain assurance
  • Favorable IP

Explore other Therapeutic categories.


  • Proton Pump Inhibitors
  • Anti-emetics
  • Anti-constipation
  • H2-receptor antagonists
  • PBC
  • Non-alcoholic steatohepatitis

PPIs- inhibit the proton (H+-K+–ATPase) pump of the parietal cells in the stomach. Anti-emetics - blocks specific receptors that respond to neurotransmitter molecules, such as serotonin, dopamine & histamine. H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells.

  • The global pandemic COVID-19 has positively affected the global gastrointestinal drug market share.
  • Owing to the increasing cases of gastric diseases, huge investments have been made by manufacturers for the development of gastrointestinal treatment.
  • The market share for GTI drugs is expected to grow in the coming years.

The global gastrointestinal drugs market is expected to grow from $46.68 billion in 2020 to $48.74 billion in 2021 at a CAGR of 4.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during COVID-19.

Used to treat people with heartburn, stomach or intestinal ulcers, or excess stomach acid. Proton pump inhibitors reduce acid by shutting down the tiny pumps within cells in your stomach that secrete it.

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

Aviso Legal

Nenhuma informação neste catálogo - incluindo qualquer referência a qualquer produto ou serviço - constitui uma oferta de venda ou deve ser interpretada como uma oferta de venda. Os produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissão regulatória, onde quer que existam tais isenções regulatórias. Os compradores devem fazer sua avaliação independente do cenário de patentes para seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas à patente. Os produtos protegidos por patentes válidas na Índia não estão disponíveis para uso comercial, mas estariam disponíveis para os propósitos da Seção 107A.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit